Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 1356 with Ritonavir in Healthy Volunteers
NCT02183441Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Primary completion
- Jun 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of BI 1356 in plasma over the time interval from 0 to 24 hours and Maximum measured concentration of BI 1356 in plasma at 96 hours. Started Apr 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183441.